在非小细胞肺癌的治疗切除后复发的动态
Yuji Muraoka1, Masaya Yotsukura1, Yukihiro Yoshida1
1Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Journal of surgical oncology
|July 17, 2023
概括
手术后的肺癌复发风险因阶段而异. 第一阶段患者的复发风险较低,而第二阶段和第三阶段需要更密切的监测. 在6年后,对新肺癌的查是关键.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 癌症流行病学 癌症流行病学
背景情况:
- 手术后肺癌复发是一个重大问题.
- 了解危险趋势对于优化患者随访至关重要.
研究的目的:
- 根据病理阶段分析术后肺癌复发风险的趋势.
- 为了比较复发风险与第二次原发性肺癌的发展.
主要方法:
- 1987年肺癌切除患者 (2007-2012) 的回顾性审查.
- 无复发生存率 (RFS) 和危险率的分析.
- 评估第二次原发性肺癌发病率.
主要成果:
- 五年RFS概率:第一阶段 (87.8%),第二阶段 (54.7%),第三阶段 (33.4%).
- 第一个阶段显示RFS危险性始终低 (<0.005).
- 第二阶段和第三阶段在手术后12-14个月左右呈现危险峰值,随后下降. 第二种原发性肺癌的风险超过了6年后复发的风险.
结论:
- 对于I期肺癌,可能不需要密集监测.
- 考虑对II/III期肺癌复发进行密切监测.
- 对第二次原发性肺癌的查比在手术后六年内复发的监测更有益.
相关概念视频
01:21Cancer Survival Analysis
394
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
394
02:40Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K